Publications
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"Receiver operating characteristic curves and confidence bands for support vector machines." Biometrics 77, no. 4 (2021): 1422-1430.
"Response to reader reaction." Biometrics 71, no. 1 (2015): 267-273.
"Risk calculators are useful but..." J Thorac Cardiovasc Surg 151, no. 3 (2016): 706-707.
"A robust method for estimating optimal treatment regimes." Biometrics 68, no. 4 (2012): 1010-8.
"ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72.
"Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Secondary outcome analysis for data from an outcome-dependent sampling design." Stat Med 37, no. 15 (2018): 2321-2337.
"Semiparametric Bayesian local functional models for diffusion tensor tract statistics." Neuroimage 63, no. 1 (2012): 460-74.
"Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome." Biostatistics 12, no. 3 (2011): 521-34.
"Semiparametric sieve maximum likelihood estimation under cure model with partly interval censored and left truncated data for application to spontaneous abortion." Lifetime Data Anal 25, no. 3 (2019): 507-528.
"Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI." Neuroimage 56, no. 3 (2011): 890-906.
"SGPP: spatial Gaussian predictive process models for neuroimaging data." Neuroimage 89 (2014): 70-80.
"A simple and robust method for multivariate meta-analysis of diagnostic test accuracy." Stat Med 36, no. 1 (2017): 105-121.
"Simulation of brain mass effect with an arbitrary Lagrangian and Eulerian FEM." Med Image Comput Comput Assist Interv 13, no. Pt 2 (2010): 274-81.
"SMAC: Spatial multi-category angle-based classifier for high-dimensional neuroimaging data." Neuroimage 175 (2018): 230-245.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
"Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
"Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer." J Thorac Oncol 14, no. 2 (2019): 298-303.
"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"TwinMARM: two-stage multiscale adaptive regression methods for twin neuroimaging data." IEEE Trans Med Imaging 31, no. 5 (2012): 1100-12.
"A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard." Biometrics 71, no. 2 (2015): 538-47.
"Using decision lists to construct interpretable and parsimonious treatment regimes." Biometrics 71, no. 4 (2015): 895-904.
"Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
"Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
"Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
"Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups." Lung Cancer 90, no. 2 (2015): 281-7.
"Variable selection for optimal treatment decision." Stat Methods Med Res 22, no. 5 (2013): 493-504.
"